Zagora Sophia L, McCluskey Peter
aSave Sight Institute, Discipline of Ophthalmology, Sydney Medical School, University of Sydney bSydney Eye Hospital, Sydney, Australia.
Curr Opin Ophthalmol. 2014 Nov;25(6):495-501. doi: 10.1097/ICU.0000000000000098.
This article reviews recent advances in the understanding of the ocular manifestations of seronegative spondyloarthropathies.
Ocular inflammatory disorders are common and important disease manifestations in patients with seronegative spondyloarthropathy, with anterior uveitis being the most common. There is a strong association between affected patients and the human leukocyte antigen B27. Local corticosteroid treatment is usually effective, but chronic or refractory uveitis responds well to immunosuppressive drugs that are effective for arthritis. Recent studies have highlighted the possible benefits of a number of biologic agents, including tumor necrosis factor-alpha inhibitors in such patients.
Uveitis is the most common ocular manifestation in patients affected by seronegative spondyloarthropathies. Both genetic and environmental factors play a role in its pathogenesis. As it tends to affect the young adult population, it carries a significant personal and population burden. Immunomodulatory therapy that also acts as a corticosteroid sparing therapy can be effective in controlling chronic uveitis in patients with spondyloarthropathy.
本文综述了血清阴性脊柱关节病眼部表现认识方面的最新进展。
眼部炎性疾病在血清阴性脊柱关节病患者中常见且为重要的疾病表现,其中前葡萄膜炎最为常见。受累患者与人类白细胞抗原B27之间存在很强的关联。局部皮质类固醇治疗通常有效,但慢性或难治性葡萄膜炎对治疗关节炎有效的免疫抑制药物反应良好。最近的研究强调了多种生物制剂在此类患者中的潜在益处,包括肿瘤坏死因子-α抑制剂。
葡萄膜炎是血清阴性脊柱关节病患者最常见的眼部表现。遗传和环境因素在其发病机制中均起作用。由于它倾向于影响年轻成年人群,因此带来了重大的个人和人群负担。作为一种可减少皮质类固醇用量的免疫调节疗法,对控制脊柱关节病患者的慢性葡萄膜炎可能有效。